Purple Biotech Ltd - ADR
PPBT
Get informed when a big investor buys or sells
+ FollowMarket Cap$231.98K
Close$
$1.76
10.9% downside
Current Fair Value
10.9% downsideOvervalued by 10.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $231,981.00 |
|---|---|
| Enterprise Value | $-4,736,019.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-5.5 |
| Beta | -0.54 |
| Outstanding Shares | 10,862,065 |
Return
| Return on Equity | -202.44% |
|---|---|
| Return on Assets | -175.36% |
| Return on Invested Capital | -197.90% |
Valuation & Multiples
| P/E Ratio | -0.01 |
|---|---|
| PEG | 0.01 |
| Price to Sales | - |
| Price to Book Ratio | 1.98 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.19 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.06 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 7, 2026
EPS Estimate
$-0.98
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
$-2.88
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 380.00% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.81%▼ 3251.19% |
|---|---|
| Total Invested | $305,645▼ 40.45% |
| Investors Holding | 14▼ 6.00% |
ESG Score
No data
About Purple Biotech Ltd
CEO: Itzhak Israel